Species differences in structure, function and metabolism have attracted attention in the last twenty years and the liver is frequently a key to these differences. The need to extrapolate from animal data in the fields of drug and chemical safety evaluation and of risk assessment has posed several questions concerning species differences. In addition, it is clear that animal models of human diseases may facilitate therapeutic research and that the detailed study of disease processes in animals may provide clues to the aetiology of some human diseases.
Species differences in structure and function Some anatomical species differences were described by Professor R J Roberts in relation to fish. Some species of fish, such as cod and herring, have a simple liver resembling that of higher animals, whilst many tropical fish, catfish and salmon have an hepatopancreas, with pancreatic tissue distributed along the major veins within the liver parenchyma. Fish have accumulations of melanomacrophages in the liver which are part of the APUD sy §tem and may play some role in metabolic detoxification of xenobiotics, as they increase in number following treatment with the nitrosamines.
Another species difference in structure and function between fish and higher animals is that in fish Kupffer cells are not present in the liver, but instead the atrium of the heart is lined by Kupffer-like cells. The result is that bacteria and toxins which would accumulate in the liver of higher animals, and would do no more than cause minimal focal necrosis, may be rapidly fatal in the fish due to myocardial necrosis.
Some functional species differences also may be of significance. For example, fish fed on rancid fish waste may accumulate fat in many tissues including the liver, which becomes very friable and readily ruptures. Like man, the fish is what he eats, and this provides the fascinating prospect of using diet to 'lipid tailor' the fish so that its flesh becomes high in polyunsaturated fats and consequently highly marketable as a 'health food'.
Species differences in metabolism
Species differences in the metabolism of xenobiotics were described by Professor R L Smith. The basic pathways are remarkably constant across all species and can be divided into the Phase I and Phase II reactions. Phase I reactions are basically those of oxidation, reduction and hydrolysis and are far more important than Phase II in determining the biological activity of a chemical. The reactions are numerous and diverse, but rarely differ qualitatively between species. However, apparently minor differences may determine whether a compound is a carcinogen or not. For example, N2-fluorenylacetamide requires metabolic activation by Nhydroxylation in order to become a proximate carcinogen. In man, around 14% of a dose will be N-hydroxylated, whilst 25-30% undergoes 7-Chydroxylation. Thus a proximate carcinogen is formed in man. In the guinea-pig, 73% of the dose undergoes 7-C-hydroxylation and none is N-hydroxylated, thus explaining why N2-fluorenylacetamide is not a carcinogen in the guinea-pig.
Even within a species, there may be considerable strain differences in the metabolic pathways involved. For example, the DA rat has impaired oxidative metabolism of several compounds, such as phenacetin and hexobarbitone, whereas the oxidative metabolism of other drugs is unaltered, e.g. tolbutamide or acetanilide.
The Phase II reactions show more qualitative interspecies variation, with some species forming unusual conjugates, e.g. the rat forms aspartic acid and serine conjugates of DDA (a metabolite of DDT). The origins of species differences in xenobiotic metabolism lie in their genetic and enzymatic diversity, which may be manifest in terms of the relative levels of the various cytochrome P-450 isozymes seen in different species and strains.
Despite the fact that species differences in metabolism have been known for a century and despite the increasing knowledge about the genetic basis for this diversity, it is still very difficult to make predictions from animals to man. Even within a species, particularly for man, considerable heterogeneity exists, making interspecies extrapolation an impossible task.
Hepatitis in man and animal species Dr R Tedder described the different forms of hepatitis which occur in man, pointing out that not only shellfish, but also raspberry parfait provides a good means of transmission of hepatitis A due to poor hygiene in the raspberry picking fields.
Hepatitis B was described by Dr Tedder as 'a virus for all seasons'. It is certainly a very economical virus, with highly conserved genetic material: only 3000 base pairs can be read in three different frames to make at least four gene products with considerable overlap. There are certain parallels in its epidemiology with the AIDS virus. In addition, despite being a DNA virus, the hepatitis B virus also replicates by means of a reverse transcriptase. Very similar hepatitis viruses exist in other species, notably in the Peking duck and in the woodchuck, providing good animal models.
In order to eradicate the disease it is essential to address the problem of persistently infected carriers. The use of serum markers to identify these people will facilitate the process.
The role of hepatitis B virus in human liver carcinogenesis was discussed by Dr B C Portmann, who suggested that the virus may be a direct carcinogen or, alternatively, might require the action of another factor, such as a mycotoxin, in order to induce carcinomas. The role of aflatoxin in hepatotoxicity and carcinogenesis was discussed by both Professor Roberts and by Dr P Grasso. Both man and many animal species have been shown to be susceptible to aflatoxin carcinogenesis, so the question is whether we can assume that man also will be susceptible to other mutagenic chemicals which have been demonstrated to induce cancer in experimental animals. Rodents are highly susceptible to liver tumour formation due to non-genotoxic agents such as phenobarbitone and BHT, which do not cause any liver damage but do result in liver enlargement. The hazard posed to man by this type of chemical is probably negligible. Liver neoplasm in animals and man Dr Grasso pointed out some of the numerous problems encountered in carcinogenesis bioassays, where the principal finding was an increase in liver tumour incidence in the treated group. For example, dietary factors have a profound influence on the background incidence of spontaneous liver tumours, with feeding of a high-protein or high-fat diet resulting in an increased incidence, whilst restriction of caloric intake reduces the background incidence. An additional problem is that of genetic drift where the spontaneous incidence of hepatic tumours, even within one strain, changes quite significantly over a few years.
Very few human tumours have ever been predicted from the results of animal studies and one of the rare instances of this occurring is that of the angiosarcomas of the liver induced by vinylchloride monomer (VCM), where Maltoni's experiments predated the discovery of the same tumour in man by a few months. This is a very rare tumour in both man and animals and is known to be induced in man by VCM and by Thorotrast.
Certain differences exist in the range of histological tumour types seen in man and animals. In man, hepatocellular carcinoma is much the most common tumour, outnumbering cholangiocarcinoma by 10:1. Non-epithelial liver tumours are extremely rare in man. In animals, tumours may arise from every component cell and may occur in livers which are already damaged, e.g. by carbon tetrachloride or the nitrosamines, or in apparently undamaged tissue. In man, it seems that the majority of hepatocellular carcinomas arise in damaged liver, the incidence of carcinoma being greatly increased by the presence of longstanding cirrhosis of any aetiology.
Cholangiocarcinoma is not seen spontaneously in rats or mice and the bile duct tumours which are chemically induced, for example by the nitrosamines, are usually benign. In contrast, in areas of the world where infestation by the liver fluke Clonorchis sinensis is common, cholangiocarcinoma is frequently seen in man.
Conversely, with the exception of the angiosarcomas induced by VCM and Thorotrast, liver sarcomas are not seen in man, whereas in experimental animals infested by the larvae (Cysticercus fasciolaris) of the cat tapeworm (Taenia crassicollis), sarcomatous change is often seen in the capsule of the larval cyst. Grasso considers that this may be analogous to the subcutaneous sarcomas induced by implanted material.
Kupffer cell tumours do not seem to exist in man, but can be induced in rodents by the nitrosamines and by trypan blue.
Portmann described the liver lesions thought to be induced by oral contraceptives (OC). Focal nodular hyperplasia (FNH) is a distinct pathological entity and is completely unrelated to the hyperplastic nodules seen in experimental animals, which are often considered to be preneoplastic lesions. FNH consists of a well demarcated nodular tumour with a distinctive central scar. Histologically, broad bands of connective tissue containing large vessels and many bile ducts separate areas of quite normal hepatocytes. The incidence of this lesion is similar in infants, children and adults of both sexes and is not affected by the use of the OC. It is generally considered to be a hamartoma. However, use of the OC does seem to lead to an increase in the size and vascularity of FNH, and OC users have an increased tendency to haemorrhage, so that the lesion is more likely to be detected in these people.
Hepatocellular adenoma is almost exclusively seen in OC users and undergoes regression on cessation of OC use. It is thus perhaps analogous to the hyperplastic nodules seen in rodents. As with FNH, the hepatocellular adenomas tend to be very vascular, with fragile vessels in continuity with the arterial system. Thus haemorrhage is a common cause of presentation and may lead to death.
The risk of carcinoma developing in OC users is very difficult to assess. An eightfold increase in risk has been suggested, but the spontaneous incidence is so low that even this does not represent a significant level.
With the exception of the OC users, the chance of a hepatocellular carcinoma arising in a noncirrhotic liver is extremely small. The real frequency of tumours in cirrhotic livers is probably underestimated for two reasons. Firstly, in many of the countries with a high incidence of liver tumours, postmortem examinations are rarely carried out so that the exact relationship between cirrhosis and carcinoma cannot be determined. Secondly, it is easy to miss small nodules of tumour in a highly nodular cirrhotic liver seen at necropsy. Histologically a reticulin stain is helpful, because reticulin is sparse or absent in areas of neoplasia but copious in cirrhotic liver. In patients with haemochromatosis, the tumour cells are unable to synthesize haemosiderin and therefore the tumour nodules will stain negatively for iron. Clinically, the development of tumour in a cirrhotic liver can be detected by a rise in the serum alphafetoprotein (a-FP) level.
Response to chemotherapy can also be monitored by measuring a-FP.
In summary, despite broad similarities between species as diverse as fish and man in terms of structure, function and metabolism and consequently in their susceptibility to infectious and toxic agents, apparently quite minor species differences result in considerable difficulty in interspecies extrapolation. However, animals may still serve as useful models of human disease, for example viral hepatitis in the woodchuck, and are an essential part of safety evaluation studies for drugs and chemicals. Caution must be exercised in interpretation of the results, particularly in the field of carcinogenesis. 
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